AR130877A1 - N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estas - Google Patents
N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estasInfo
- Publication number
- AR130877A1 AR130877A1 ARP230102864A ARP230102864A AR130877A1 AR 130877 A1 AR130877 A1 AR 130877A1 AR P230102864 A ARP230102864 A AR P230102864A AR P230102864 A ARP230102864 A AR P230102864A AR 130877 A1 AR130877 A1 AR 130877A1
- Authority
- AR
- Argentina
- Prior art keywords
- dmt
- composition
- dimethyltryptamine
- amorphous
- polymeric carrier
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 12
- 238000000034 method Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 abstract 11
- 239000011159 matrix material Substances 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 1
- 241000416162 Astragalus gummifer Species 0.000 abstract 1
- 229920001661 Chitosan Polymers 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 102000004856 Lectins Human genes 0.000 abstract 1
- 108090001090 Lectins Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 229920002125 Sokalan® Polymers 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 229920002807 Thiomer Polymers 0.000 abstract 1
- 229920001615 Tragacanth Polymers 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 229940072056 alginate Drugs 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000002523 lectin Substances 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 230000003232 mucoadhesive effect Effects 0.000 abstract 1
- 239000001814 pectin Substances 0.000 abstract 1
- 229920001277 pectin Polymers 0.000 abstract 1
- 235000010987 pectin Nutrition 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940074982 poly(vinylpyrrolidone-co-vinyl-acetate) Drugs 0.000 abstract 1
- 229920000058 polyacrylate Polymers 0.000 abstract 1
- 239000004584 polyacrylic acid Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 229940068984 polyvinyl alcohol Drugs 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 229940029039 propylene glycol alginate ester Drugs 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 235000010487 tragacanth Nutrition 0.000 abstract 1
- 239000000196 tragacanth Substances 0.000 abstract 1
- 229940116362 tragacanth Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/974,443 US20230136824A1 (en) | 2021-04-26 | 2022-10-26 | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130877A1 true AR130877A1 (es) | 2025-01-29 |
Family
ID=90832092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102864A AR130877A1 (es) | 2022-10-26 | 2023-10-26 | N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estas |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4608395A2 (fr) |
| AR (1) | AR130877A1 (fr) |
| AU (1) | AU2023367107A1 (fr) |
| CA (1) | CA3267555A1 (fr) |
| TW (1) | TW202423415A (fr) |
| WO (1) | WO2024092106A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182156A1 (fr) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Nouvelles compositions de matiere et compositions pharmaceutiques |
| US12378194B2 (en) | 2021-05-25 | 2025-08-05 | Atai Therapeutics, Inc. | N, n-dimethyltryptamine salts and crystalline salt forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021003467A1 (fr) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Compositions de dosage et procédés d'utilisation de composés psychédéliques |
| US20210015738A1 (en) * | 2019-07-17 | 2021-01-21 | Concept Matrix Solutions | Oral dissolvable film containing psychedelic compound |
| CA3182156A1 (fr) * | 2020-05-08 | 2021-11-11 | Psilera Inc. | Nouvelles compositions de matiere et compositions pharmaceutiques |
| EP3941904A1 (fr) * | 2020-06-12 | 2022-01-26 | Beckley Psytech Limited | Composition pharmaceutique comprenant de la 5-méthoxy-n, n-diméthyltryptamine |
| CA3192617A1 (fr) * | 2020-09-20 | 2022-03-24 | Matthew BAGGOTT | Compositions de tryptamine avantageuses pour troubles mentaux ou amelioration mentale |
| BR112023022195A2 (pt) * | 2021-04-26 | 2024-01-16 | Atai Therapeutics Inc | Novas composições e métodos de n,n-dimetiltriptamina |
-
2023
- 2023-10-26 TW TW112141056A patent/TW202423415A/zh unknown
- 2023-10-26 EP EP23883743.9A patent/EP4608395A2/fr active Pending
- 2023-10-26 AR ARP230102864A patent/AR130877A1/es unknown
- 2023-10-26 CA CA3267555A patent/CA3267555A1/fr active Pending
- 2023-10-26 WO PCT/US2023/077879 patent/WO2024092106A2/fr not_active Ceased
- 2023-10-26 AU AU2023367107A patent/AU2023367107A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4608395A2 (fr) | 2025-09-03 |
| TW202423415A (zh) | 2024-06-16 |
| AU2023367107A1 (en) | 2025-03-27 |
| CA3267555A1 (fr) | 2024-05-02 |
| WO2024092106A3 (fr) | 2024-06-06 |
| WO2024092106A2 (fr) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130877A1 (es) | N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estas | |
| US11806347B2 (en) | Transmucosal methods for treating psychiatric and neurological conditions | |
| EP1408034B2 (fr) | Utilisation des dérivés des quinolones et quinolizinones comme agents chemothérapeutiques | |
| US5900247A (en) | Mucoadhesive pharmaceutical composition for the controlled release of active principles | |
| CA2751884C (fr) | Administration transdermique de tamsulosine | |
| EP3843729A1 (fr) | Nouvelles compositions et méthodes | |
| US20130310462A1 (en) | Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair | |
| JPH06305958A (ja) | 消炎鎮痛外用貼付剤 | |
| AU7723894A (en) | Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof | |
| CA2784587A1 (fr) | Formes pharmaceutiques se presentant sous la forme de films administrables par voie orale contenant de l'ondansetron | |
| US11738006B2 (en) | Pharmaceutical composition containing antifungal agent as active ingredient | |
| Mishra et al. | Plasticizers: A vital excipient in novel pharmaceutical formulations | |
| Nair et al. | Mucoadhesive buccal patch of cefixime trihydrate using biodegradable natural polymer | |
| US20050214230A1 (en) | Novel stomatological gel | |
| Pv et al. | Formulation design and evaluation of bilayer buccal tablets of granisetron hydrochloride | |
| IE60458B1 (en) | Enhanced bioavailability adsorbates | |
| US20230331762A1 (en) | Crystalline form of aspacytarabine | |
| KR20020012978A (ko) | 진통소염 효과를 갖는 디클로페낙염을 함유 카타플라스마제 | |
| GB2173101A (en) | Dopaminergic composition containing dihydroergocryptine | |
| KR102860999B1 (ko) | 졸피뎀 또는 이의 약제학적으로 허용되는 염의 구강점막 용액 | |
| WO2025110709A1 (fr) | Composition pour la prévention ou le traitement d'une maladie parodontale et composition d'onguent antibiotique composite dentaire | |
| RO137880A2 (ro) | Compoziţie de sistem mucoadeziv pentru eliberarea topică a doxicilinei la nivelul cavităţii orale | |
| US20130184239A1 (en) | Combination of siloxane and active ingredient for treating dental disorder | |
| Willcox | Treatment implications of the lessened sensitivity of the gonococcus to penicillin | |
| WO2025230326A1 (fr) | Composition ophtalmique comprenant de la pilocarpine |